Engineered for high-performance workflows, the Apostle MiniMax® High-Efficiency Isolation Kits support rare mutation detection, small RNA profiling and multimodal analysis
INDIANAPOLIS – (April 22, 2026) – Beckman Coulter Life Sciences, a Danaher company and a global leader in research laboratory instruments, automation and genomic solutions, today announced expanded access to Apostle MiniMax® High-Efficiency Isolation Kits that enable researchers to isolate cfDNA, cfRNA and total cfNA from liquid biopsy samples—supporting more complete, multimodal genomic analysis from limited inputs. Developed by Apostle Inc., the kits are now available globally through Beckman Coulter Life Sciences commercial channels.
This expansion builds on the companies’ established partnership, which previously introduced the Apostle MiniMax® High Efficiency Cell-Free DNA Isolation Kit through a distribution agreement. The collaboration pairs Apostle’s proprietary magnetic nanoparticle technology with Beckman Coulter Life Sciences global reach, liquid handling automation and expertise in supporting high-throughput genomic workflows.
“We’ve long invested in genomic solutions that reduce complexity and improve productivity,” says Sudharshana Seshadri, Vice President, Product Management, Beckman Coulter Life Sciences. “With broader access to Apostle MiniMax® extraction kits—adding cfRNA and total cfNA solutions to the cfDNA kit already offered—laboratories can achieve high-yield purification for liquid biopsy workflows from limited samples and maintain confidence in downstream NGS and PCR applications.”
Together, the Apostle MiniMax® cfDNA, cfRNA, and total cfNA kits address persistent challenges in liquid biopsy workflows, including recovering highly fragmented cfDNA, isolating fragile small RNAs, and enabling multimodal analysis from limited samples while producing clean, high-yield, high-quality cell-free nucleic acids for NGS and PCR applications.
“We are seeing interest in cfRNA/cfNA extractions from labs that have been using cfDNA analyses. This follows a trend that we’ve previously experienced with FFPE samples in tumor characterization, where it has now become standard to analyze RNA and DNA from the same sample," says Milan Dieris, Field Application Specialist, Beckman Coulter Life Sciences.
Learn more about Apostle MiniMax® Kits at beckman.com/reagents/genomic/cell-free-dna-rna-extraction-kits.
Products and applications are not intended or validated for use in diagnostic procedures.
About Beckman Coulter Life Sciences
Time is the most critical facet in the laboratory today: time to get life-saving therapies to patients faster; reclaiming time by automating tedious manual workflows; and saving time otherwise spent addressing erroneous or complex results.
At Beckman Coulter Life Sciences, a Danaher company, we are partners in time. We accelerate answers to critical questions through the power of efficiency, saving hours from some workflows and delivering reliable results in centrifugation, flow cytometry, genomic solutions, particle analysis/counters, and liquid handlers.
We develop innovations for scientists by scientists, with many of our 3,300+ global colleagues coming from the laboratory with a deep understanding of today’s challenges and complexities. We’re passionate about translating science in partnership with our customers, and our customizable, accessible and sustainable solutions empower them with intuitive workflow efficiencies.
Time and again customers put their trust in us, with 400,000+ of our built-to-last products currently delivering results in labs worldwide—all backed by our dependable service and application experts offering educational insights and tailored support.
It’s all part of our time-tested approach since 1935 to bring meaningful innovations at the speed of life—and we’re just beginning. Working together, let’s advance human health for a better tomorrow!
Get to know us by clicking here and by following us on LinkedIn.
About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
Media Contact:
Amber Smock,
Marketing Communications Manager
[email protected]
2026-GBL-EN-109526-v1
